000157626 001__ 157626
000157626 005__ 20240229123142.0
000157626 0247_ $$2doi$$a10.2147/CLEP.S256662
000157626 0247_ $$2pmid$$apmid:32821171
000157626 0247_ $$2pmc$$apmc:PMC7417931
000157626 0247_ $$2altmetric$$aaltmetric:88686347
000157626 037__ $$aDKFZ-2020-01723
000157626 041__ $$aeng
000157626 082__ $$a610
000157626 1001_ $$0P:(DE-He78)98a8f1a22ffc460364a8a34499118103$$aZheng, Guoqiao$$b0$$eFirst author$$udkfz
000157626 245__ $$aIncidence Differences Between First Primary Cancers and Second Primary Cancers Following Skin Squamous Cell Carcinoma as Etiological Clues.
000157626 260__ $$aAlbany, Auckland$$bDove Medical Press$$c2020
000157626 3367_ $$2DRIVER$$aarticle
000157626 3367_ $$2DataCite$$aOutput Types/Journal article
000157626 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1683892555_20086
000157626 3367_ $$2BibTeX$$aARTICLE
000157626 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157626 3367_ $$00$$2EndNote$$aJournal Article
000157626 500__ $$a#EA:C050#LA:C050#LA:C020#
000157626 520__ $$aMost literature on second primary cancers (SPCs) focuses on possible factors, which may increase the risk of these cancers, and little attention has been paid for the overall incidence differences between first primary cancers (FPCs) and same SPCs. We wanted to compare the incidence rates for all common cancers when these were diagnosed as FPCs and SPCs after invasive and in situ squamous cell carcinoma (SCC) of the skin, which are usually treated by surgery only.Cancers were identified from the Swedish Cancer Registry from the years 1990 through to 2015, and they included, in addition to skin cancers, 20 male cancers totaling 484,850 patients and 22 female cancers totaling 452,909 patients. Standardized incidence rates and relative risks (RRs) were calculated for sex-specific common cancers as FPC and as SPC after skin SCC. Spearman rank correlations were used in the analysis of incidence ranking of FPC and SPC.Of total, 29,061 men and 23,533 women developed invasive SCC and 27,842 men and 36,383 women in situ SCC. The total number of 20 other male cancers was 484,850 and of 22 female cancers it was 452,909. Rank correlations ranged from 0.90 to 0.96 (P~5×10-6), indicating that overall skin SCC did not interfere with SPC formation. The exceptions were increased SPC risks for melanoma, sharing risk factors with skin SCC, and non-Hodgkin and Hodgkin lymphoma, and cancers of the upper aerodigestive tract, connective tissue, and male and female genitals suggesting contribution by skin cancer initiated immune dysfunction.The incidence ranking of SPCs after skin cancers largely follows the incidence ranking of FPCs indicating that overall skin SCC does not greatly interfere with the intrinsic carcinogenic process. The main deviations in incidence between FPC and SPC appeared to be due to shared risk factors or immunological processes promoting immune responsive cancer types.
000157626 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000157626 588__ $$aDataset connected to CrossRef, PubMed,
000157626 7001_ $$aSundquist, Kristina$$b1
000157626 7001_ $$00000-0001-7228-5015$$aSundquist, Jan$$b2
000157626 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b3$$udkfz
000157626 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b4
000157626 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b5$$eLast author$$udkfz
000157626 773__ $$0PERI:(DE-600)2494772-6$$a10.2147/CLEP.S256662$$gVol. 12, p. 857 - 864$$p857 - 864$$tClinical epidemiology$$v12$$x1179-1349$$y2020
000157626 909CO $$ooai:inrepo02.dkfz.de:157626$$pVDB
000157626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)98a8f1a22ffc460364a8a34499118103$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000157626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000157626 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000157626 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000157626 9141_ $$y2020
000157626 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN EPIDEMIOL : 2018$$d2020-01-16
000157626 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-16
000157626 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-16
000157626 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-16
000157626 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-01-16
000157626 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-01-16
000157626 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-01-16
000157626 915__ $$0LIC:(DE-HGF)CCBYNCNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial CC BY-NC (No Version)$$bDOAJ$$d2020-01-16
000157626 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-16
000157626 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-16
000157626 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-16
000157626 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-16
000157626 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-16
000157626 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-01-16
000157626 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-16
000157626 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-16
000157626 9201_ $$0I:(DE-He78)C050-20160331$$kC050$$lMolekular-Genetische Epidemiologie$$x0
000157626 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000157626 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x2
000157626 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x3
000157626 980__ $$ajournal
000157626 980__ $$aVDB
000157626 980__ $$aI:(DE-He78)C050-20160331
000157626 980__ $$aI:(DE-He78)HD01-20160331
000157626 980__ $$aI:(DE-He78)B062-20160331
000157626 980__ $$aI:(DE-He78)C020-20160331
000157626 980__ $$aUNRESTRICTED